Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05677893 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase 1 study, sponsored by Oneness Biotech Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT05677893 is a Phase 1 study that has completed, run by Oneness Biotech Co.. The registered enrollment target is 44 participants.
The verdict
NCT05677893, a Phase 1 study, has completed, sponsored by Oneness Biotech Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
Interventions
- OTHER Placebo
- DRUG MBS-COV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05677893
The ClinicalTrials.gov registry entry for NCT05677893 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oneness Biotech Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05677893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05677893 about?
NCT05677893 is a clinical study titled "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants". A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
What is the current status of trial NCT05677893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-11-07. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT05677893?
The interventions under investigation include: Placebo (OTHER), MBS-COV (DRUG).
Who is sponsoring clinical trial NCT05677893?
This trial is sponsored by Oneness Biotech Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.